3E Bioventures
Edit

3E Bioventures

http://www.3ebiovc.com
Last activity: 28.04.2022
Active
Invests in categories: BiotechnologyDevelopmentDrugHealthTechMedTechPlatformProductionTechnologyTherapeuticsTools
3E Bioventures Capital is a healthcare focused fund dedicated to investing in frontier technologies. We mainly invest in two areas: innovative therapeutic drugs and disruptive cross disciplinary med-tech in medical devices and diagnostics.
News
65
Portfolio
34
Persons
6
Mentions
5
Employees: 11-50
Investment Stage: Series A

Portfolio 34

DateNameWebsiteTotal RaisedLocation
24.05.2023Larkspur B...larkspur.bio$35.5MUnited Sta...
03.03.2022Dermaliqdermaliq.com$15M-
07.02.2022Dewpoint T...dewpointx.com$227MUnited Sta...
19.01.2022Bayland Sc...baylandscientific.com-United Sta...
22.12.2021Bayland Sc...wenxintech.com--
22.12.2021Cognition ...cogrx.com$182.24MUnited Sta...
22.12.2021ITabMeditabmed.com--
27.08.2021Acclarofa-in.com-United Sta...
07.06.2021Alveo Tech...alveotechnologies.com$38MUnited Sta...
07.06.2021Sentieonsentieon.com-United Sta...
Show more

Persons 6

DateFirst NameLast NameTitleLinkedInLocation
-Christine ...WuInvestment...linkedin.c...-
-LindaLiu-linkedin.c...-
-KarenLiuPartnerlinkedin.c...-
-CiaoZhangInvestment...linkedin.c...-
-LueSun-linkedin.c...-
-S. FrankYanPartnerlinkedin.c...-

News 65

DateTitleDescription
27.04.2022OncoC4 Announces Fast Track Designation Granted by the U.S. FDA for ONC-392 Monotherapy in PD(L)1-Resistant NSCLC-
12.04.2022Apexigen Announces New Data from a Phase 2 Trial Evaluating its CD40 Antibody, Sotigalimab, in Combination with Pembrolizumab in Patients with Metastatic Melanoma Presented at the AACR Annual Meeting ...-
06.04.2022Using AI-Based Image Enhancement to Reduce Brain MRI Scan Times and Improve SNR-
31.03.2022DR. YANG LIU ACKNOWLEDGED AS TOP 20 DYNAMIC CEOS OF 2022-
19.03.2022Apexigen and Brookline Capital Acquisition Corp. Announce Business Combination Agreement to Create Publicly Listed Immuno-oncology Company-
17.03.2022ONCOC4 RECOGNIZED AS A TOP 10 IMMUNOTHERAPY SOLUTIONS PROVIDERS-
09.03.2022C4 Therapeutics Announces FDA Orphan Drug Designation for CFT8634 for the Treatment of Soft Tissue Sarcoma-
28.02.2022Twist Bioscience Becomes Digital Preservation Coalition Supporter-
04.02.2022Dewpoint Therapeutics Announces Completion of $150 Million Series C Financing-
27.01.2022Twist Bioscience Signs Collaboration with Artisan Bio to Engineer Next Generation Cell Therapeutics-
Show more

Mentions in press and media 5

DateTitleDescription
30.08.2021Chinese brain science company Neural Galaxy raises $77m led by 3E BioventuresBeijing-based brain science company Neural Galaxy announced on Monday that it has completed a Series A round of financing, raising 500 million yuan ($77 million) led by returning investor 3E Bioventures. New investor Lotus Lake Capital ente...
30.08.2021Chinese brain science company Neural Galaxy raises $77m led by 3E BioventuresPremium Beijing-based brain science company Neural Galaxy announced on Monday that it has completed a Series A round of financing, raising 500 million yuan ($77 million) led by returning investor 3E Bioventures. Continue reading this story ...
24.05.2021Eliem Therapeutics, Inc. announced that it has received $60 million in funding from Intermediate Capital Group plc, RA Capital Management, L.P., Access Biotechnology, Samlyn Capital, LLC, Acorn Bioven...On May 24, 2021, Eliem Therapeutics, Inc. closed the transaction. The company announced that it has received $60,000,000 in its series B round of funding co-led by returning investors RA Capital Management, L.P. and Intermediate Capital Gro...
23.11.2020Subtle Medical cierra una ronda Serie A de $12,2M liderada por 3E Bioventures. Acuden Fusion Fund, Data Collective, Delta Capital, Tsingyuan Ventures, Crista Galli y Nina Capital23/11/2020 SUBTLE MEDICAL CIERRA UNA RONDA SERIE A DE $12,2M LIDERADA POR 3E BIOVENTURES CAPITAL. ACUDEN FUSION FUND, DATA COLLECTIVE, DELTA CAPITAL, TSINGYUAN VENTURES, CRISTA GALLI Y NINA CAPITAL. La compañía estadounidense Subtle Medic...
12.01.2017OncoImmune Closes $15.0M Series A Funding RoundOncoImmune, a Rockville, Maryland clinical-stage biopharmaceutical company, closed $15.0m Series A funding round. The round was led by 3E Bioventures Capital. The company intends to use the funds to develop a novel clinical stage asset targ...

Reviews 0

Sign up to leave a review

Sign up Log In